FDA Approves Sublocade, A Once-Monthly Buprenorphine Injection

On November 30, 2017, the U.S. Food and Drug Administration (FDA) announced it had approved a once-monthly buprenorphine injection called Sublocade to be used as a medication assisted treatment (MAT) option for adults moderate-to-severe opioid use disorder. The approval was granted to Indivior Inc. a subsidiary of Indivior PLC, which was formerly known as Reckitt Benckiser Pharmaceuticals, Inc. Indivior manufactures and distributes pharmaceutical products; it offers the branded buprenorphine-based medications Suboxone and Subutex (a sublingual tablet) for opioid use disorder treatment. Indivior anticipates a marketing launch during the first quarter of 2018.

Sublocade is intended . . .